Organization | Apollo Hospitals, Chennai, India

Apollo Hospitals, Chennai, India Report issue

Academic/Hospital Phase 1 Phase 3

Founded: Chennai India (1983)

Organization Overview

First Clinical Trial

2005

NCT00500409

First Marketed Drug

2017

tazobactam (Zosyn)

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

APOLLO | Apollo Gleneagles Hospitals, Kolkata | Apollo Hospital, New Delhi, India | Apollo Hospitals, Ahmedabad | Apollo Hospitals, Hyderabad, AP, India | Apollo Hospitals, Hyderabad, India | Indraprastha Apollo Hospital, New Delhi

Active Ingredients

Marketed Drugs (6)

dihydroergotamine (D.H.E. 45) (2020)

ergoloid mesylate (2020)

phenylephrine (Prefrin) (2020)

piperacillin (pipracil) (2017)

tazobactam (Zosyn) (2017)

tranexamic acid (cyklokapron) (2019)

Drugs in Phase 3 Trials (5)

calcium (1 trial)

epoetin (Epogen) (1 trial)

parathyroid hormone (Natpara) (1 trial)

safinamide (xadago) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 1 Trials (1)

egfrviii-specific hinge-optimized cd3 ζ-stimulatory/41bb-co-stimulatory chimeric antigen receptor autologous t-lymphocytes (1 trial)

Drugs in Other Trials (2)

epinephrine (levophed) (1 trial)

indomethacin (indocin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 3)

Kidney Failure, Chronic (Phase 3)

Osteoporosis (Phase 3)

Parkinson Disease (Phase 3)

Renal Insufficiency (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 8